Mainz Biomed Establishes Partnership with Precision for Medicine to Support ColoAlert’s U.S. Regulatory and Commercial Strategy

BERKELEY, Calif. and MAINZ, Germany, Nov. 30, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announced today the Company has engaged Precision for Medicine, a leading global Clinical Research Organization, to provide U.S. regulatory and reimbursement advisory support for ColoAlert, […]

Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board

Former Danaher executive provides significant clinical, global market, and product development expertise in cancer diagnostics BERKELEY, CA –  MAINZ, Germany – November 18, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Soren Thestrup-Nielsen M.D. […]

Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair

BERKELEY, US –  MAINZ, Germany – NOVEMBER 15, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that Company representatives will be attending MEDICA 2021 to showcase ColoAlert, its highly efficacious and easy-to-use diagnostic test for colorectal […]

Mainz Biomed Appoints Former Roche Division President Heiner Dreismann to Strategic Advisory Board

Former President and CEO of Roche Molecular Systems and Member of Roche’s Global Diagnostic Executive Committee BERKELEY, Calif. and MAINZ, Germany, Nov. 11, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Heiner Dreismann to […]

Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’

Flagship product ‘ColoAlert’ provides a unique, life-saving early detection test for colorectal cancer European registration completed and commercial rollout underway across multiple territories FDA clinical study process to be launched for U.S. regulatory approval BERKELEY, US –  MAINZ, Germany – NOVEMBER 8, 2021 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular […]

MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market

BERKELEY, US – MAINZ, Germany – NOVEMBER 5, 2021 — Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”. On November 4, 2021, the Company […]